• visiongain
    • utility utility
    • packaging packaging
    • plastics plastics
    • telecoms & IT telecoms & IT
    • metals metals
    • renewable energy renewable energy
    • defence defence
    • your guide to your industry your guide to your industry
    • pharma pharma
    • energy energy
    • aviation aviation
    • paper paper

welcome to visiongain

Visiongain is the place you need to know about to meet your most important business information needs. This portal will offer you accurate, up-to-date news and analysis on the key areas of your business sector, along with the opportunity to network with industry peers and market leaders. You can stay ahead with our:

Reports: visiongain reports cover the most important areas of your business sector. Researched by our team experts, they will provide you with accurate information and insightful analysis.

Conferences: visiongain conferences provide you with the opportunity to hear market leaders speak on the most important issues concerning your business, along with excellent networking opportunities.

Newsletters: visiongain newsletters give you access to the most important daily news affecting your industry, keeping you informed through reliable sources.

latest reports

visiongain RSS Feed
  • Next Generation FTTX: Fibre Optics Innovations 2012-2017

    The future of telecommunications is steadfastly driving towards IP convergence. Next generation networks require a reliable and future-proof base for the increasing demands of both fixed and wireless connectivity. Fibre optics communication is currently the fastest and most resilient technology available and already forms the core network of international submarine cables connecting the different regions of the world. In order to anticipate the ever-growing demand for data and the resulting traffic loads, telecom operators and governments alike are rolling-out new terrestrial fibre networks and upgrading existing copper-based ones with fibre technology. Visiongain expects the number of global FTTX subscribers to reach 148 million in 2012
  • Needle-Free Delivery: Technology and Market 2012-2022

    The technology and devices for needle-free delivery of drugs/vaccines has been available in the market since several decades. Although their market penetration has been low, the recent years have seen an increase in adoption, driven by the need for pain free delivery. Currently, the market for needle-free delivery devices is dominated by small medical device companies and academic researchers. These small scale companies are developing innovative needle-free delivery technologies, with the pharmaceutical companies entering into partnership with the device developers for using the technology for delivery of the company's drug.
  • Cell-Based Assays: World Market Prospects 2012-2022

    What does the future hold for cell-based assays in pharma? Visiongain's report shows you potential revenues and other trends, with data, forecasts and discussions. Our study analyses products and services for cell-based testing. It covers activities of product developers and pre-clinical contract research organisations. You discover sales predictions to 2022 at world market, main submarket and national levels.

upcoming conferences

visiongain RSS Feed
  • 7th Annual Pharmacovigilance Conference

    The importance of Pharmacovigilance has been apparent since the problems with thalidomide emerged in the 1960s. Since then, various high profile drug recalls, and estimations that more than 750,000 injuries and deaths each year in the US are caused by adverse drug reactions, have meant tightened regulatory controls.
  • Biobanking 2012

    As researchers strive to develop more personalised medicines, the acquisition of high quality biospecimens is vital. This is reflected in the estimation that the biobanking market will be worth $19.13 bn by 2015. Harmonising biobank operations with better communication networks and global standardisation is imperative. The biobanking and biomolecular resources research infrastructure's new model for research estimates they will have approximately 200 biobanks operating across Europe by early 2012, complying with clearly defined responsibilities, quality standards and common procedures.
  • 2nd Lyophilization Americas

    With over 130 products on the market worth $50bn, biologicals and biopharmaceuticals remain the fastest growing segment amongst novel pharmaceutical entities today. Mirroring this trend the market for lyophilizing compounds such as biologicals and biopharmaceuticals is currently approaching 200 million units and it is set to continue its year-on-year double digit growth. The lyophilisation market is expected to achieve significant growth from 2011 to 2021, owing primarily to greater demand for injectable biotech drugs and vaccine market expansion caused by the entry of new products and technologies.